Evaluation of a Pharmacogenetic-based Warfarin Dosing Algorithm in Patients
Atrial Fibrillation
About this trial
This is an interventional treatment trial for Atrial Fibrillation
Eligibility Criteria
Inclusion Criteria:
- Only patients with atrial fibrillation, above 18 years, and with TTR <50% based on the last three values of INR will be included in this study.
Exclusion Criteria:
- Patients will not be included if they have reached a stable dose of warfarin, liver dysfunction, alcoholism, use of another anticoagulant, use of chemotherapy, or if they do not meet the inclusion criteria
Sites / Locations
- Heart Institute
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
Traditional anticoagulation
Pharmacogenetic anticoagulation
For the Traditional Anticoagulation group, the physician will adjust the dose according to the current INR value based on current guidelines
For the Pharmacogenetic Anticoagulation group, the dose will be prescribed based on data from each patient applied in a pharmacogenetic algorithm. In some cases, used algorithm may provide a counter-intuitive dose, i.e., a dose that is not adequate for adjusting the current patient' INR (for example, a higher dose for a patient that already has a high INR). In these cases, the physician will adjust the dose following clinical criteria based on published guidelines